公开(公告)号：WO2010043050A1

公开(公告)日：2010-04-22

申请号：PCT/CA2009/001483

申请日：2009-10-16

Applicant: CELATOR PHARMACEUTICALS CORPORATION ,  TARDI, Paul ,  MAYER, Lawrence ,  BERMUDES, David

Inventor： TARDI, Paul ,  MAYER, Lawrence ,  BERMUDES, David

IPC: A61K31/4745 ,  A61K31/496 ,  A61K31/513 ,  A61K31/7072 ,  A61K39/395 ,  A61K9/127 ,  A61P35/00

CPC classification number: A61K9/127 ,  A61K31/4745 ,  A61K31/496 ,  A61K31/513 ,  A61K31/7072 ,  A61K39/39558 ,  A61K2300/00

Abstract: Compositions which comprise a liposomal water-soluble camptothecin and optionally a liposomal fluoropyrimidine in combination with a vascular epithelial growth factor (VEGF) inhibitor such as cetuximab or an epidermal growth factor receptor (EGFR) inhibitor such as bevacizumab are useful in achieving enhanced therapeutic effects for the treatment of cancer.

Abstract translation: 包含脂质体水溶性喜树碱和任选的脂质体氟嘧啶与血管上皮生长因子（VEGF）抑制剂如西妥昔单抗或表皮生长因子受体（EGFR）抑制剂如贝伐单抗联合的组合物可用于实现增强的治疗效果 治疗癌症。

公开(公告)号：WO2009097011A1

公开(公告)日：2009-08-06

申请号：PCT/US2008/073185

申请日：2008-08-14

Applicant: CELATOR PHARMACEUTICALS, INC. ,  TARDI, Paul ,  JOHNSTONE, Sharon ,  MAYER, Lawrence

Inventor： TARDI, Paul ,  JOHNSTONE, Sharon ,  MAYER, Lawrence

IPC: A61K9/127

CPC classification number: A61K9/127 ,  A61K9/0019 ,  A61K31/4745 ,  A61K31/555 ,  A61K33/24

Abstract: Compositions which comprise liposomes having controlled release of a platinum agent are useful in achieving enhanced therapeutic effects particularly when these drugs are administered in combination with other therapeutic agents.

Abstract translation: 包含具有铂剂的受控释放的脂质体的组合物可用于实现增强的治疗效果，特别是当这些药物与其它治疗剂组合施用时。

公开(公告)号：WO2007076117A3

公开(公告)日：2007-11-01

申请号：PCT/US2006049245

申请日：2006-12-22

Applicant: CELATOR PHARMACEUTICALS INC ,  DICKO AWA ,  TARDI PAUL ,  MAYER LAWRENCE ,  JOHNSTONE SHARON

Inventor： DICKO AWA ,  TARDI PAUL ,  MAYER LAWRENCE ,  JOHNSTONE SHARON

IPC: A61K9/127

CPC classification number: A61K9/1278

Abstract: Provided herein are liposomal compositions comprising a therapeutic agent having a protonatable amino group and a secondary or tertiary amine, and methods for encapsulating such therapeutic agents. In one aspect, the present invention relates to liposomal formulations comprising irinotecan in a triethanolamine solution, and optionally comprising copper gluconate, and methods for preparing the same.

Abstract translation: 本文提供了包含具有可质子化氨基和仲或叔胺的治疗剂的脂质体组合物，以及用于包封这些治疗剂的方法。 一方面，本发明涉及包含三乙醇胺溶液中的伊立替康和任选地包含葡萄糖酸铜的脂质体制剂及其制备方法。

公开(公告)号：WO2007035783A2

公开(公告)日：2007-03-29

申请号：PCT/US2006/036569

申请日：2006-09-19

Applicant: CELATOR PHARMACEUTICALS, INC. ,  JOHNSTONE, Sharon ,  HARVIE, Pierrot ,  TARDI, Paul ,  HARASYM, Troy ,  MAYER, Lawrence

Inventor： JOHNSTONE, Sharon ,  HARVIE, Pierrot ,  TARDI, Paul ,  HARASYM, Troy ,  MAYER, Lawrence

IPC: A61K9/127

CPC classification number: A61K9/127

Abstract: Compositions which comprise delivery vehicles having stably associated therewith a cytidine analog and a platinum agent are useful in achieving enhanced therapeutic effects when combinations of these drugs are administered.

Abstract translation: 包含稳定与胞苷类似物和铂剂相关的递送载体的组合物在施用这些药物的组合时可用于实现增强的治疗效果。

公开(公告)号：WO2006014626A3

公开(公告)日：2006-10-05

申请号：PCT/US2005025549

申请日：2005-07-19

Applicant: CELATOR PHARMACEUTICALS INC ,  UNIV PRINCETON ,  MAYER LAWRENCE D ,  PRUD HOMME ROBERT K ,  ALLEN CHRISTINE J ,  SAAD WALID S

Inventor： MAYER LAWRENCE D ,  PRUD HOMME ROBERT K ,  ALLEN CHRISTINE J ,  SAAD WALID S

IPC: A61K31/74 ,  A61K31/77

CPC classification number: A61K47/482 ,  A61K8/85 ,  A61K9/5153 ,  A61K45/06 ,  A61K47/22 ,  A61K47/48107 ,  A61K47/48192 ,  A61K47/551 ,  A61K47/552 ,  A61K47/58 ,  A61K47/59 ,  A61K47/593 ,  A61K47/60 ,  A61K47/6935 ,  A61K2800/57 ,  A61Q17/04 ,  B82Y5/00

Abstract: Particulate constructs stabilized by amphiphilic copolymers and comprising at least one active coupled to a hydrophobic moiety provide sustained release of the active in both in vitro and in vivo environments.

Abstract translation: 通过两亲性共聚物稳定并且包含至少一个与疏水部分结合的活性物质的颗粒构建物在体外和体内环境中均提供活性物质的持续释放。

公开(公告)号：WO2006014626A2

公开(公告)日：2006-02-09

申请号：PCT/US2005/025549

申请日：2005-07-19

Applicant: CELATOR PHARMACEUTICALS, INC. ,  THE TRUSTEES OF PRINCETON UNIVERSITY ,  MAYER, Lawrence, D. ,  PRUD'HOMME, Robert, K. ,  ALLEN, Christine, J. ,  SAAD, Walid, S.

Inventor： MAYER, Lawrence, D. ,  PRUD'HOMME, Robert, K. ,  ALLEN, Christine, J. ,  SAAD, Walid, S.

IPC: A61K9/14

CPC classification number: A61K47/482 ,  A61K8/85 ,  A61K9/5153 ,  A61K45/06 ,  A61K47/22 ,  A61K47/48107 ,  A61K47/48192 ,  A61K47/551 ,  A61K47/552 ,  A61K47/58 ,  A61K47/59 ,  A61K47/593 ,  A61K47/60 ,  A61K47/6935 ,  A61K2800/57 ,  A61Q17/04 ,  B82Y5/00

Abstract: Particulate constructs stabilized by amphiphilic copolymers and comprising at least one active coupled to a hydrophobic moiety provide sustained release of the active in both in vitro and in vivo environments.

Abstract translation: 通过两亲性共聚物稳定并且包含至少一种与疏水部分偶联的活性物质的微粒构建体在体内和体外都提供了活性物质的持续释放， I>的环境。

公开(公告)号：WO03041681A3

公开(公告)日：2003-09-18

申请号：PCT/CA0201726

申请日：2002-11-13

Applicant: CELATOR TECHNOLOGIES INC ,  WEBB MURRAY ,  TARDI PAUL ,  MAYER LAWRENCE D ,  ICKENSTEIN LUDGER M

Inventor： WEBB MURRAY ,  TARDI PAUL ,  MAYER LAWRENCE D ,  ICKENSTEIN LUDGER M

IPC: A61K9/127 ,  A61K9/19 ,  A61K31/704 ,  A61K31/7072 ,  A61K33/24 ,  A61K9/00

CPC classification number: A61K9/1271 ,  A61K9/127 ,  A61K9/1278

Abstract: Liposomes that contain at least 10 mol % of a negatively charged lipid coupled to an non-zwitterionic moiety are stable in the blood. Liposomes containing at least 1 mol % of such lipids may be frozen safely.

Abstract translation: 含有至少10mol％与非两性离子部分偶联的负电荷脂质的脂质体在血液中是稳定的。 含有至少1摩尔％这种脂质的脂质体可以安全冷冻。

公开(公告)号：WO2008101214A2

公开(公告)日：2008-08-21

申请号：PCT/US2008054168

申请日：2008-02-15

Applicant: CELATOR PHARMACEUTICALS INC ,  LOUIE ARTHUR ,  SWENSON CHRISTINE ,  MAYER LAWRENCE ,  JANOFF ANDREW

Inventor： LOUIE ARTHUR ,  SWENSON CHRISTINE ,  MAYER LAWRENCE ,  JANOFF ANDREW

IPC: A61K31/70 ,  A61K9/127 ,  A61P35/00

CPC classification number: A61K31/70 ,  A61K9/0019 ,  A61K9/127 ,  Y10T436/143333

Abstract: Provided herein are methods for treating cancer by administering a pharmaceutical composition comprising a fixed, non-antagonistic molar ratio of cytarabine and an anthracycline. Such methods are particularly useful in the treatment of patients with advanced hematologic cancers or proliferative disorders.

Abstract translation: 本文提供了通过施用包含固定的非拮抗摩尔比的阿糖胞苷和蒽环霉素的药物组合物来治疗癌症的方法。 这些方法在治疗晚期血液癌症或增殖性疾病的患者中特别有用。

公开(公告)号：WO2007064978A2

公开(公告)日：2007-06-07

申请号：PCT/US2006/046159

申请日：2006-11-30

Applicant: CELATOR PHARMACEUTICALLS, INC. ,  MAYER, Lawrence

Inventor： MAYER, Lawrence

IPC: A61F2/02

CPC classification number: A61L31/16 ,  A61L31/10 ,  A61L2300/61

Abstract: Implants comprising controlled delivery matrices, associated with, or including medical devices, having stably and releasably associated therewith predetermined non- antagonistic combinations of two or more therapeutic agents provide control of the ratio of these agents at a localized site. Methods of identifying such combinations are also disclosed.

Abstract translation: 包含受控递送基质的植入物，与或具有医疗装置相关联或包含医疗装置的植入物，其具有稳定和可释放地与两种或更多种治疗剂的预定非拮抗性组合相关联，提供了这些药剂在局部位点处的比率的控制。 还公开了鉴定这种组合的方法。

公开(公告)号：WO2006081354A3

公开(公告)日：2006-08-03

申请号：PCT/US2006/002782

申请日：2006-01-26

Applicant: CELATOR PHARMACEUTICALS, INC. ,  TARDI, Paul ,  MAYER, Lawrence ,  CABRAL-LILLY, Donna

Inventor： TARDI, Paul ,  MAYER, Lawrence ,  CABRAL-LILLY, Donna

IPC: A61K9/127

Abstract: The invention relates to a method for reducing the polydispersity of a population of gel-phase lipid-based delivery vehicles.